Dynavax Technologies (United States)

CpG 1018 and alum synergistically enhance systemic and mucosal immunity to an N2 neuraminidase vaccine

Recombinant neuraminidase (rNA) is a promising target for broadly protective influenza vaccine development but typically requires adjuvants, especially for intranasal (IN) delivery. We evaluated an N2 rNA vaccine construct (globular head domain of NA, stabilized with a measles vi...